CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 64 enrolled
Drug / intervention
Adrenocorticotropic Hormonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02290444
NCT02290444Phase 3Completed
CompareCT.gov

Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis

State University of New York at Buffalo·interventional·Posted Nov 14, 2014·Updated Apr 6, 2020

In Brief

A Phase 3 clinical trial evaluating Adrenocorticotropic Hormone for Multiple Sclerosis. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 14, 2014
Enrollment StartAug 1, 2013
Primary CompletionNov 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 11.6 years ago

Interventions

Adrenocorticotropic Hormonedrug

Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.